ADAPYAdaptimmune Therapeutics Plc - ADR

$0.0304
$0.0021
(6.46%)
Today
Updated: 03:59 PM EDT
Reported EarningsAug 13
Mkt Cap$8.06M
Vol945,291.00

About

Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
N/A

Frequently Asked Questions

What is Market Cap of Adaptimmune Therapeutics Plc - ADR?
What is the 52-week high for Adaptimmune Therapeutics Plc - ADR?
What is the 52-week low for Adaptimmune Therapeutics Plc - ADR?
What is Adaptimmune Therapeutics Plc - ADR stock price today?
What was Adaptimmune Therapeutics Plc - ADR stock price yesterday?
What is the PE ratio of Adaptimmune Therapeutics Plc - ADR?
What is the Price-to-Book ratio of Adaptimmune Therapeutics Plc - ADR?
What is the 50-day moving average of Adaptimmune Therapeutics Plc - ADR?

Latest ADAPY News

View

Advertisement|Remove ads.

Advertisement|Remove ads.